Roche Holding AG (RHHBF)
OTCMKTS · Delayed Price · Currency is USD
425.00
+5.00 (1.19%)
At close: Dec 23, 2025
Roche Holding AG Revenue
Roche Holding AG had revenue of 31.85B CHF in the half year ending June 30, 2025, with 4.03% growth. This brings the company's revenue in the last twelve months to 63.49B, up 4.80% year-over-year. In the year 2024, Roche Holding AG had annual revenue of 62.40B with 3.23% growth.
Revenue (ttm)
63.49B CHF
Revenue Growth
+4.80%
P/S Ratio
4.47
Revenue / Employee
614.90K CHF
Employees
103,249
Market Cap
356.60B USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 62.40B | 1.95B | 3.23% |
| Dec 31, 2023 | 60.44B | -5.37B | -8.16% |
| Dec 31, 2022 | 65.81B | -36.00M | -0.05% |
| Dec 31, 2021 | 65.85B | 5.51B | 9.13% |
| Dec 31, 2020 | 60.34B | -3.41B | -5.35% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Jushi Holdings | 260.43M |
| Glass House Brands | 196.17M |
| Elite Pharmaceuticals | 122.89M |
| Silence Therapeutics | 25.83M |
| OpGen | 9.00M |
| Northwest Biotherapeutics | 937.00K |
Roche Holding AG News
- 20 hours ago - US Drug Pricing Deal May Lead to Swiss Medicine Price Hikes - IBTimes
- 2 days ago - Roche (RHHBY) CEO Predicts Drug Price Increase in Switzerland - GuruFocus
- 2 days ago - Roche: FDA Approves Lunsumio VELO Under Accelerated Approval - Nasdaq
- 2 days ago - Roche CEO expects surge in drug prices in Switzerland after U.S. deal - Seeking Alpha
- 2 days ago - FDA Approves Genentech's Lunsumio VELO™ for Subcutaneous Use in Relapsed or Refractory Follicular Lymphoma - Business Wire
- 2 days ago - Trump tariffs push Swiss pharma CEO to urge price alignment with US - South China Morning Post
- 3 days ago - Roche CEO points to higher future drug prices in Switzerland after US deal - Reuters
- 3 days ago - Roche CEO points to higher future drug prices in Switzerland after US deal - Yahoo